OBJECTIVES: Transcatheter aortic valve implantation (TAVI) has emerged rapidly. Despite unanimous recommendations and potentially fatal intraoperative complications, the heart-team approach is not comprehensively adopted by all centres. We sought to characterize severe intraprocedural complications during TAVI requiring immediate surgical or interventional bailout manoeuvres and evaluate outcomes.
INTRODUCTION
The efficacy and safety of transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis and contraindications or high risk for conventional surgery have been demonstrated [1, 2] . Procedure numbers have increased significantly over the past years, and TAVI is already being employed in >30% of isolated aortic valve replacements in Germany [3] . The heart-team approach has been recommended for this procedure unanimously by the societies and has recently been implemented into the European guidelines on the treatment of valvular disease [4] . However, despite well-known and potentially fatal intraoperative complications, the heart-team approach is not comprehensively performed by all centres in Germany. Even more, some authors suggest that rare intraprocedural complications during TAVI requiring complex surgical treatment are associated with disproportionally high mortality and rather futile outcomes, therefore questioning the prerequisite of institutionalized departments of cardiology and cardiac surgery at sites performing TAVI [5] .
We sought to characterize severe intraprocedural complications during TAVI requiring emergent surgical or interventional bailout manoeuvres at our institution, evaluate outcomes and investigate the utility of a dedicated heart-team-based approach in this scenario.
METHODS

Patient population
From March 2008 through February 2012, 458 consecutive patients underwent transfemoral or transapical TAVI with first and second generation devices for severe aortic stenosis at our institution. All patients presented with severe comorbidities precluding them from surgical aortic valve replacement as determined by an interdisciplinary heart team. In addition to routine examinations, preprocedural workup included transoesophageal echocardiography, coronary angiography and contrast-enhanced multislice computed tomography to evaluate access and device choice, as previously described [6] .
Procedure
TAVI was performed in a specially equipped hybrid suite under general anaesthesia in all cases by an interdisciplinary heart team of cardiac surgeons, interventional cardiologists and anaesthesiologists. Perfusionists were present during the procedure and a prepared heart-lung-machine was available in the hybrid suite. Transapical and transfemoral access was gained in the usual fashion and TAVI employing the Edwards Sapien and Sapien XT (Edwards Lifesciences, Irvine, CA, USA), Medtronic CoreValve Revalving System (Medtronic, Minneapolis, MN, USA), JenaValve ( JenaValve Technology GmbH, Munich, Germany) and Symetis Accurate (Symetis S.A., Ecublens, Switzerland) devices was performed, as previously described [7] [8] [9] [10] [11] . A percutaneous closure device (Prostar XL, Abbott Vascular, Abbott Park, IL, USA) was utilized after the introduction of the Sapien XT device for all transfemoral cases.
Clinical follow-up, data management and analysis
All relevant baseline, procedural and follow-up data were prospectively collected and entered into a dedicated database. The median follow-up duration was 262.5 days. Outcomes were analysed in accordance with the standardized end-points defined by the Valve Academic Research Consortium (VARC) [12] .
The overall patient population was retrospectively divided into the following groups: Patients who experienced severe intraprocedural complications requiring immediate surgical or interventional treatment (COMP) vs patients who did not suffer from these adverse events (noCOMP). Furthermore, patients were stratified according to those who needed emergent intraprocedural sternotomy and conversion to surgical therapy (CONV) vs those who did not require emergent conversion (noCONV).
Categorical data were presented as count (percentages) and compared with Fisher's exact test. Continuous data were presented as means ± standard deviation and compared with the unpaired t-test. Event rates were represented using Kaplan-Meier estimates and compared with log-rank tests. A landmark analysis was performed to evaluate cumulative survival after 30 days. P-values were reported without correction for multiple testing. Level of significance was set to two-tailed P < 0.05. Statistical analysis was performed using SPSS version 20 and GraphPad Prism version 6.0.
Ethics
All patients were fully informed about the procedure and signed written consent forms.
RESULTS
Baseline characteristics
Baseline patient characteristics are detailed in Table 1 . Overall age was 80.6 ± 7.0 years with 52.2% female patients and a mean logistic EuroSCORE of 22.2 ± 13.6%. Demographics were comparable between COMP and noCOMP as well as CONV and noCONV patients. However, there was a trend towards fewer relevant baseline comorbidities in patients experiencing intraprocedural complications when compared with the overall population, resulting in lower logistic EuroSCOREs. There were no significant differences in complication rates with regard to transfemoral and transapical access.
Intraprocedural complications
Intraprocedural complications during TAVI requiring surgical or interventional management occurred in 7.6% of all TAVI cases. Overall, 35 patients suffered from 40 major complications (COMP group, Table 2 ). Sternotomy and conversion to surgical therapy were required in 2.8% of patients (CONV group), 53.8% of whom underwent transfemoral TAVI. Complications concerning adequate placement of the transcatheter heart valve within the aortic annulus accounted for the majority (39%) of complications, combining valve embolization and migration (17%), severe aortic regurgitation (12%), implant failure (5%) and root rupture (5%), requiring subsequent implantation of a second valve or conversion to surgical valve replacement ( Fig. 1A and B). While valve embolization or migration into the ascending aorta was managed sufficiently with valve-in-valve implantation in the majority of patients, dislocation into the left ventricle or left ventricular outflow tract was followed by immediate conversion to surgical aortic valve replacement. Main causes of embolization and migration were suboptimal positioning, insufficient oversizing, scarce calcification or extrasystoly during implantation. Two failures to deliver the transcatheter heart valve at the aortic annulus required pullback of the device, implantation into the descending aorta and implantation of a second device in the Subdividing the overall TAVI population into quartiles according to procedure date, a decrease of complication and conversion rates from quartiles 1 to 4 becomes evident (9.6 vs 3.5% and 1.7 vs 0.9%, Fig.1C ).
Postprocedural outcomes
Ten of 35 COMP patients (28.6%) died in the early postoperative period (0-6 days) due to procedure-related complications. The remaining 25 patients survived and were either alive at the latest follow-up or died unrelated to the procedure and due to other causes during mid-term follow-up. Of the subgroup of patients who underwent conversion to surgery (CONV), 5 of 13 patients died in the early postoperative period (0-3 days) due to procedure-related complications.
VARC-defined end-points are detailed in Table 3 . Postprocedural complications and composite safety end-points were reached more frequently in COMP and CONV patients. Rates of major Outcomes of patients according to the Valve Academic Research Consortium (VARC) with regard to severe intraprocedural complications requiring immediate surgical or interventional treatment (COMP vs noCOMP) or the need for emergent intraprocedural sternotomy and conversion to surgery (CONV vs noCONV). Acute kidney injury was classified according to the 'modified' RIFLE criteria [12, 21] . PRBC: packed red blood cells. Values are presented as median (interquartile range) or frequencies and percentages. A two-tailed P < 0.05 was considered statistically significant (bold).
stroke (14.3 and 15.4%) and stage-3 acute kidney injury (8.6 and 7.7%) were higher. Owing to the rate of bleeding events associated with the vascular or access-related complications, the amount of transfused packed red blood cells was likewise significantly increased in COMP and CONV patients (4 and 13 units). Similarly, the length of stay in hospital was longer (10 and 13.5 days). All-cause mortality at 30 days was significantly higher in COMP vs noCOMP patients (31.4 vs 7.8%, P < 0.001) and CONV vs noCONV patients (38.5 vs 8.8%, P = 0.005). Kaplan-Meier plots ( Fig. 2A and B) illustrate differences in cumulative 1-year survival in COMP vs noCOMP patients (49.7 vs 71.8%, P < 0.001) and CONV vs noCONV patients (51.3 vs 70.6%, P = 0.06). However, a landmark analysis revealed a comparable cumulative survival after 30 days in COMP vs noCOMP patients (Fig. 2C) . At 30 days, NYHA functional class of surviving patients did not differ significantly between patients with and without severe intraprocedural complications (COMP vs noCOMP: 2.2 ± 0.5 vs 2.1 ± 0.7; P = 0.346) or with and without emergent conversion to surgery (CONV vs noCONV: 2.3 ± 0.5 vs 2.1 ± 0.7; P = 0.342).
DISCUSSION
Severe intraprocedural complications requiring immediate surgical or interventional management occurred in a relevant number of TAVI procedures (7.6%). The majority of intraprocedural complications arose from problems with adequate placement, anchoring or sealing of the transcatheter heart valve within the aortic annulus, resulting in migration, embolization or significant aortic regurgitation. Supra-annular device dislocation or severe aortic regurgitation was managed successfully with transcatheter valve-in-valve implantation in most patients. Overall, 2.2% of patients underwent implantation of more than one valve, comparing favourably with 1.1-3.6% reported by others [1, 2, [13] [14] [15] . Embolization of the valve prosthesis into the left ventricle or migration into the left ventricular outflow tract required conversion to surgical aortic valve replacement. Overall, rates of intraprocedural sternotomy and conversion to surgery were low (2.8%) and in line with other publications, reporting conversion rates of 0-2.7% [1, 2, [13] [14] [15] [16] [17] [18] [19] . Furthermore, all-cause mortality after conversion or valve-in-valve implantation in patients with prosthesis dislocation or relevant aortic regurgitation was acceptable with 14.3% at 30 days. A combination of learning curve effects, advanced imaging and further device modifications towards a controlled release, as already implemented in some of the second generation and investigational devices, may further decrease these event rates in the future.
Cardiac tamponade due to left ventricular wire perforation was evident in 2.5% of transfemoral TAVI procedures (1.1% of overall procedures), confirming the rates reported by others [16] , and required emergent sternotomy in all patients. Pericardiocentesis is frequently employed to relieve cardiac tamponade. Owing to the severe course within the operating room and the availability of immediate sternotomy, this procedure was performed in all patients to identify the source of bleeding and initiate adequate treatment. Two of the 5 patients died within the first 24 h after intervention due to procedure-related complications, emphasizing the need for meticulous surveillance of the stiff guidewire within the left ventricle. The majority of wire perforations occurred during the early transfemoral experience, suggesting that this complication can be prevented with increasing operator experience. Coronary complications during valve deployment were described at rates of 0-1.1% in the literature [2, 15, 16, 18] and became evident in 1.3% of cases in our experience, caused by occlusion of the coronary ostia, thrombo-embolism or dissection into the coronary arteries. Despite rapid intervention, acute survival of these patients was markedly reduced, with an acute mortality of 3 of 6 patients. Contrary to the well-described adverse impact of major vascular complications on survival after TAVI [20] , no negative effect was observed in the reported 8 patients who required intraprocedural vascular surgery for failed percutaneous vascular closure. This effect may be owed to the small patient numbers and focus on immediate surgical revision rather than VARC-defined vascular complication end-points. Overall, particular VARC-adjusted postoperative adverse events were significantly more frequent in patients with intraprocedural complications or conversion to surgery, with higher rates of major strokes or acute kidney injury. However, these numbers have to be interpreted with caution due to the vast difference in group sizes and the small frequency of events.
Regardless of transfemoral or transapical approaches, TAVI is generally performed under general anaesthesia at our institution. In our opinion, this may add safety to the procedure due to controlled conditions without the need for emergent endotracheal intubation in case of severe complications and the opportunity to perform intraprocedural transoesophageal echocardiography. However, to further investigate this perception, an analysis of outcomes after complicated TAVI employing conscious sedation would be of importance.
Most likely reflecting the learning curve, we observed a considerable reduction in rates of intraprocedural complications and conversions to surgery over time, as has been well documented for the transapical approach before [18] . Consistent with this effect, technical and anatomical rather than comorbidity-related issues seem to be responsible for the described complications, as baseline characteristics even trended towards a lower estimated perioperative risk in patients who required emergent intraprocedural surgical or interventional management.
Limitations of the study include its retrospective nature and the small study size, particularly with respect to the COMP and CONV groups, impeding and potentially distorting direct comparison. Nonetheless, this report facilitated the assessment of the incidence and nature of intraprocedural complications in a real-world TAVI scenario, allowing for evaluation of potential bailout options. Despite significant early mortality in these patients, mid-term survival after 30 days was comparable with the overall TAVI population, as demonstrated by a landmark analysis. A multidisciplinary team with equal contribution by cardiologists and cardiac surgeons alike facilitated bailout procedures and accomplished acceptable outcomes in a heart-team effort. An excellent cooperation between anaesthesiologists and perfusionists and a prepared heart-lung-machine in the hybrid suite are of paramount importance. Although a further decrease in intraprocedural complications can be anticipated with growing experience and improved technical preconditions in the future, a surgical and interventional safety net should be sustained in all centres performing TAVI procedures at this point in time. The sole performance of TAVI by cardiologists in a cath-lab with the lack of appropriate bailout options in case of complications contravenes current guidelines and constitutes a dangerous approach, in our opinion. 
APPENDIX. CONFERENCE DISCUSSION
Dr L. Harling (London, UK): I completely agree with you that a heart team approach is vital in all cases of TAVI. There are a couple of interesting things from your data. First of all, you said that your baseline demographics were comparable between the two groups. I noticed from reading your original paper that actually you had a higher pre-procedural EuroSCORE in the no complication patients compared to the complication patients. I wonder if you could explain that a bit further, if you had any insights into whether this represents differences such as a staff or procedural preference, or a change in technique? Dr Seiffert: That is a very good question. I think it is quite difficult to interpret these data and compare the two groups with respect to the EuroSCORE because they are fairly skewed and group size differs considerably.
We were surprised by the fact that you mentioned as well, and I would interpret it in a way that the risk profiles at baseline do not actually translate into intraprocedural complication rates. It is rather that the patient's individual anatomical or clinical factors, or technical issues during the procedure, translated into complications and conversions. Hence, we don't think that the classical risk assessment tools that we frequently use are prognostic markers or predictors in these cases.
Dr Harling: Do you think that perhaps we should think about a different risk score and profiling system for such patients.
Dr Seiffert: Maybe. Dr Harling: My second question was about your learning curve. It is very interesting to see the data of your learning curve over the time that you have been performing the procedure. You showed that you had avoidable vs nonavoidable complications in the way that you described the majority of complications being as a result of misplacement of the valve in one way or another. Do you think that this profile changed over time? As you changed your learning curve, did that profile of complications change? Dr Seiffert: We haven't really looked into that yet in detail, to be honest. If I think back, vascular complications, for example, decreased as we started using smaller sheaths and smaller devices, and I would anticipate that the implantation, especially with the second-generation devices, becomes more controlled and better predictable. So I would anticipate that those numbers would decrease, but we haven't analysed that in particular.
Dr T. Walther (Bad Nauheim, Germany): In the end you said that the complication rate is going down. Do you expect that it will go down to zero at some point? Dr Seiffert: I don't believe so. What is more important, though, if the complication rate goes down to zero, there might be one point where people say, well, why do we need surgeons anymore, right? That is the question behind that. Why do we need a heart team if there are no complications anyway? But I don't think we will get to that point, because, as opposed to PCI, for example, it is a more complex and haemodynamically challenging procedure. So I think complications will decrease but will not reduce to zero, and I believe it is crucial to keep the heart team approach.
Dr Walther: We will need surgeons because we are the experts in treating aortic valve disease, and we know how these valves look, and basically we have to make clear to patients and to cardiologists that some things are unpredictable. The anatomy of the patient is very variable, and some cardiologists I think don't have an idea of what these massive amounts of calcium sometimes look like, and this will lead to, I predict, some uncertain procedures. It won't change.
Dr N. Moat (London, UK): It is a very nice piece of work and an important piece of work and I think all of us would agree with your conclusions. At the risk of being a little blunt, this is not how this was presented at TCT in a plenary session on Friday, in that the cardiological community was suggesting that all of these centres that are doing TAVI in Germany have a full heart team approach; the surgeons are completely involved in patient selection and implantation. I think this is a really important question. So is that true, or is it more in line with what you are saying today, because that was a big plenary session at TCT and a very different message was put out.
Dr Seiffert: Well, there is actually a paper out from a group of cardiologists which would suggest that institutionalized cardiac surgery and cardiology within one department is not a prerequisite for TAVI Dr Moat: So you are saying that that is actually happening in Germany, that there are cardiology units doing TAVI without a fully integrated surgical service?
Dr Seiffert: Right. Dr C. Huber (Bern, Switzerland): There was actually a committee paper in Germany issued last year clearly requesting a multidisciplinary true heart team approach in German centres.
Dr T. Walther (Bad Nauheim, Germany): To try to answer part of your question, unfortunately there are centres who do TAVI without surgeons on board, and many others, centres like Hamburg and our centre, who have a clear heart team, and always try to counteract that. But Fred Mohr mentioned yesterday that the DRG may have come too early and the method has spread all over already.
I put it a bit differently when speaking to Mike Mack. I said that the Americans can be happy to have the FDA, which regulated this whole business, and regulated it very clearly, incorporating the views of cardiac surgeons. Now in the US you don't get any reimbursement if you don't have a heart team. And in Germany at present there may be developments that some cases will not be reimbursed, but I haven't heard that that has happened, cases where there is no heart team. Do you know about some in Hamburg?
Dr H. Treede (Hamburg, Germany): To answer Neil's point, there are different situations in Germany. You have centres with full heart teams and you have cardiologists performing TAVIs by themselves. There is a working group among the German Cardiac Society of Interventional Cardiologists which strongly believes that TAVI can be done by cardiologists alone. And they say, well, what happens if there is a complication? That was the sense of this paper. They say, well, they die anyway. And that was our point: they do not die anyway. If they are properly treated, okay, they have a mortality of 30%, but this means two-thirds of the patients survive, and I think those patients merit having a cardiac surgeon and a full team in the room. And I think we must emphasize that over and over again, put it in the guidelines and whatever. But we are not perfect in Germany. Surely a third of the TAVIs are done by cardiologists alone at the moment.
